PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20610983-6 2010 Although new triazole antifungals are well tolerated, they still cause significant inhibition of CYP enzymes. Triazoles 13-21 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 97-100 22701192-7 2012 Concomitant administration of medications such as triazole antifungals which influence the cytochrome P-450 system can exacerbate this potential complication of ATRA. Triazoles 50-58 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 91-107 21995615-0 2011 Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450. Triazoles 0-8 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 68-83 21995615-2 2011 As substrates and inhibitors of cytochrome P450 (CYP), the triazoles can interact with many drugs, which may lead to enhanced toxicity of the concomitant medication(s) or ineffective antifungal treatment. Triazoles 59-68 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 32-47 21995615-2 2011 As substrates and inhibitors of cytochrome P450 (CYP), the triazoles can interact with many drugs, which may lead to enhanced toxicity of the concomitant medication(s) or ineffective antifungal treatment. Triazoles 59-68 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 49-52 21995615-4 2011 AREAS COVERED: This manuscript reviews the role of human hepatic CYP in triazole-drug interactions, illustrates how recent discoveries in pharmacogenetics and triazole metabolism impact our understanding of these interactions, and summarizes the most clinically important triazole-drug interactions. Triazoles 72-80 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 65-68 21995615-4 2011 AREAS COVERED: This manuscript reviews the role of human hepatic CYP in triazole-drug interactions, illustrates how recent discoveries in pharmacogenetics and triazole metabolism impact our understanding of these interactions, and summarizes the most clinically important triazole-drug interactions. Triazoles 159-167 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 65-68 21995615-4 2011 AREAS COVERED: This manuscript reviews the role of human hepatic CYP in triazole-drug interactions, illustrates how recent discoveries in pharmacogenetics and triazole metabolism impact our understanding of these interactions, and summarizes the most clinically important triazole-drug interactions. Triazoles 159-167 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 65-68 21995615-5 2011 A search of English language, original research and scholarly reviews describing interactions between triazole antifungal agents and human CYP published from 1980 to present was undertaken using PubMed. Triazoles 102-110 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 139-142 21995615-6 2011 EXPERT OPINION: Triazoles interact with many drugs and the primary mechanism for these interactions is hepatic CYP. Triazoles 16-25 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 111-114 21995615-8 2011 However, advances in genotyping, improved analytical technology and bioanalytical methods, which enable accurate molecular identification and stereochemical analysis, have substantially added to the understanding of the role hepatic CYP plays in triazole-drug interactions in humans. Triazoles 246-254 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 233-236 30429697-3 2018 Triazole antifungals are known inhibitors of cytochrome P450 (CYP) enzymes. Triazoles 0-8 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 45-60 19519346-1 2009 Drug interactions occur frequently with triazole antifungal agents because of their properties as inhibitors of 1 or more phase 1 (cytochrome P450) biotransformation enzymes and, possibly, as inhibitors or substrates of a phase 2 biotransformation enzyme or transporter protein. Triazoles 40-48 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 131-146 19196220-2 2009 Posaconazole, an extended-spectrum triazole, is an inhibitor of the cytochrome P450 (CYP) isoenzyme CYP3A4, and sirolimus, an immunosuppressant, is a substrate of the enzyme. Triazoles 35-43 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 68-83 19196220-2 2009 Posaconazole, an extended-spectrum triazole, is an inhibitor of the cytochrome P450 (CYP) isoenzyme CYP3A4, and sirolimus, an immunosuppressant, is a substrate of the enzyme. Triazoles 35-43 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 85-88 8247921-1 1993 Fluconazole is a triazole antifungal agent reported to have a low affinity for human cytochrome P-450, and thus would not be expected to interact with drugs metabolized through the cytochrome P-450 system, including phenytoin, cyclosporine, and warfarin. Triazoles 17-25 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 85-101 1311944-2 1992 Agents such as substituent imidazoles and triazoles, which act by inhibiting the fungal cytochrome P-450-dependent enzyme lanosterol N-demethylase, have the potential to inhibit host cytochrome P-450-dependent drug metabolism. Triazoles 42-51 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 88-104 1311944-2 1992 Agents such as substituent imidazoles and triazoles, which act by inhibiting the fungal cytochrome P-450-dependent enzyme lanosterol N-demethylase, have the potential to inhibit host cytochrome P-450-dependent drug metabolism. Triazoles 42-51 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 183-199 19026034-4 2008 Systemic triazoles are inhibitors of cytochrome P450 (CYP) isozymes, such as CYP3A4, CYP2C9 and CYP2C19, to varying degrees. Triazoles 9-18 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 37-52 19026034-4 2008 Systemic triazoles are inhibitors of cytochrome P450 (CYP) isozymes, such as CYP3A4, CYP2C9 and CYP2C19, to varying degrees. Triazoles 9-18 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 54-57 17573638-1 2007 trans-Bromuconazole is a chiral chemical representative of a class of triazole derivatives known to inhibit specific fungal cytochrome P-450 (CYP) reactions. Triazoles 70-78 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 124-140 17573638-1 2007 trans-Bromuconazole is a chiral chemical representative of a class of triazole derivatives known to inhibit specific fungal cytochrome P-450 (CYP) reactions. Triazoles 70-78 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 142-145 18690854-16 2007 These interactions are caused by the metabolism of triazoles in the liver where the cytochrome P450 (CYP) system is involved at a different extend as well as by their mechanisms of action. Triazoles 51-60 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 84-99 18690854-16 2007 These interactions are caused by the metabolism of triazoles in the liver where the cytochrome P450 (CYP) system is involved at a different extend as well as by their mechanisms of action. Triazoles 51-60 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 101-104 18611706-1 1996 Itraconazole is an orally active, broad-spectrum, triazole antifungal agent which has a higher affinity for fungal cytochrome P-450 than ketoconazole but a low affinity for mammalian cytochrome P-450. Triazoles 50-58 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 115-131 8043490-15 1994 Non-steroidal inhibitors of cytochrome P-450 enzymes, such as imidazole and triazole derivatives have been developed which are highly selective for aromatase. Triazoles 76-84 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 28-44 1951574-7 1991 Most of the imidazole and triazole derivatives are highly potent and selective inhibitors of the cytochrome P-450-dependent 14 alpha-demethylation of lanosterol (P-45014DM). Triazoles 26-34 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 97-113 1951574-9 1991 The triazole antifungals, terconazole and itraconazole, combine a high affinity for Candida P-45014DM with an exceptionally low effect on mammalian cytochrome P-450. Triazoles 4-12 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 148-164 2677363-5 1989 However, because of the additional nitrogen atom in the triazole ring and the lipophilic tail, terconazole establishes a firmer and longer-lasting link with the membrane-bound fungal cytochrome P-450. Triazoles 56-64 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 183-199 30429697-3 2018 Triazole antifungals are known inhibitors of cytochrome P450 (CYP) enzymes. Triazoles 0-8 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 62-65 23514038-3 2013 Brz2001 is a brassinosteroid biosynthesis inhibitor in the less-soluble triazole series of compounds that targets DWARF4, a cytochrome P450 (Cyp450) monooxygenase containing heme and iron. Triazoles 72-80 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 124-139 29022838-4 2017 Areas covered: This manuscript reviews the pharmacogenomics (i.e. the influence of genetics on drug disposition) of triazole antifungal agents related to their CYP-mediated metabolism and summarizes their implications on triazole efficacy, safety, and tolerability. Triazoles 116-124 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 160-163 29022838-4 2017 Areas covered: This manuscript reviews the pharmacogenomics (i.e. the influence of genetics on drug disposition) of triazole antifungal agents related to their CYP-mediated metabolism and summarizes their implications on triazole efficacy, safety, and tolerability. Triazoles 221-229 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 160-163 23514038-3 2013 Brz2001 is a brassinosteroid biosynthesis inhibitor in the less-soluble triazole series of compounds that targets DWARF4, a cytochrome P450 (Cyp450) monooxygenase containing heme and iron. Triazoles 72-80 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 141-147